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ABSTRACT
Background. Survival among dialysis patients with diabetes mellitus (DM) is inferior to survival of non-diabetic dialysis
patients, probably due to the higher prevalence of diabetes-related comorbid conditions. One could hypothesize that these
comorbid conditions also contribute to a decreased survival after amputation in diabetic patients compared with non-
diabetic patients on dialysis.
Methods. Data were collected from the Netherlands Cooperative Study on the Adequacy of Dialysis, a multicentre,
prospective cohort study in which new patients with end-stage renal disease were monitored until transplantation or
death. Amputation rates (incident cases) were calculated in patients with and without DM. The primary endpoint was all-
cause survival after first amputation during dialysis therapy in diabetic patients compared with non-diabetic dialysis
patients with an amputation. This was formally assessed using interaction analysis (Poisson regression).
Results. During follow-up (mean duration 2.9 years), 50 of the 413 diabetic patients had a new amputation (12.1%), compared
with 20 of 1553 non-diabetic patients (1.2%). Amputation rates/1000 person-years were 47.9 [95% confidence interval (CI) 36.3–
63.2] and 4.1 (95% CI 2.7–6.4), respectively, for diabetic patients and non-diabetic patients. Amputation increased mortality
risk more than 4-fold in patients without diabetes [hazard ratio (HR) 4.6 (95% CI 2.8–7.6)] as well as in patients with diabetes
[HR 4.6 (95% CI 3.3–6.4)]. No formal interaction between diabetes and amputation was found (P¼0.12).
Conclusions. Amputation in dialysis patients is associated with a 4-fold increased mortality risk; this mortality risk was
similar for diabetes and non-diabetes patients. Importantly, the risk for amputation is 10-fold higher in DM compared with
non-diabetic dialysis patients.
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INTRODUCTION
Diabetes mellitus (DM) is the most common underlying cause of
non-traumatic amputation. The main factors associated with
diabetes-related amputation are sensory neuropathy, infection
and ischaemia [1–5]. Another common cause of amputation is
chronic kidney disease, with the highest risk in patients with end-
stage renal disease (ESRD) [6]. Furthermore, several studies have
shown an  10-fold increased amputation risk in diabetic dialysis
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patients compared with non-diabetic dialysis patients, although
risk estimates showed a variation among different countries [7, 8].
Studies on survival after amputation in diabetic and non-
diabetic patients with and without ESRD thus far have shown
contrasting results. In some studies, diabetes was associated
with an excess mortality after amputation [9, 10], whereas other
studies showed similar or reduced mortality in diabetic patients
compared with non-diabetic patients [7, 11–15]. Another study
reported a time-dependent impact of diabetes on mortality,
with a lower mortality in the first 2–3 years, but thereafter dia-
betic patients had a higher mortality compared with non-dia-
betic patients [16]. These contrasting results might be due to
different study populations, different follow-up times and dif-
ferent statistical approaches.
The primary aim of this study was to compare the survival
after amputation in diabetic dialysis patients with that of non-
diabetic dialysis patients using a cohort study with long-term
follow-up. The secondary aim of this study was to determine the
incidence of a recurrent amputation in diabetic dialysis patients.
MATERIALS AND METHODS
Design
The Netherlands Cooperative Study on the Adequacy of Dialysis
(NECOSAD) is a prospective, multicentre cohort study in 38 dialy-
sis centres throughout the Netherlands in which incident
patients with ESRD were included at the time of initiation of dial-
ysis treatment, from 1 January 1997 until 1 January 2007. Study
visits took place at the start of dialysis, at 3 and 6 months and
subsequently at 6-month intervals until the date of censoring
(death, kidney transplantation or transfer to a non-participating
dialysis centre) or the end of the follow-up on 1 January 2007.
Data on demographic characteristics and comorbidities were col-
lected at the time of entry into the study. Dialysis characteristics
were collected 3 months after the start of RRT and at 6-month
intervals thereafter. At the 3-month visit, patients were classi-
fied according to the treatment modality, that is, haemodialysis
(HD) or peritoneal dialysis. The cause and type of renal disease
were defined according to the criteria of the European Renal
Association–European Dialysis and Transplantation Association
[17]. For each patient, data on DM were collected, such as insulin
dependency, patient-reported duration of DM and history of dia-
betic retinopathy for which laser therapy was performed. During
each study visit, patients were asked if they had been operated
on and/or admitted to the hospital. Surgical (operation) proce-
dures on and dates were documented. Furthermore, hospital
admissions and the reason for admission were registered.
Patient selection
Patients 18 years of age who started with dialysis as the initial
renal replacement therapy were eligible for this study. Start of
dialysis was considered as baseline and start of follow-up, ex-
cept for analyses concerning treatment modality, in which case
3 months was considered as baseline; the reason is that after
3 months, most patients are considered to be on a ‘definitive’ di-
alysis mode. Informed consent was obtained before inclusion.
This study was approved by the medical ethics committees of
all participating centres.
Exposures and study outcomes
For all patients we extracted data on amputations; levels of
amputations were categorized as toe(s), feet, below knee and
above knee. Toe(s) and feet amputations were classified as mi-
nor amputation, whereas below knee and above knee were clas-
sified as major amputations. Second, amputations were
classified as either prevalent (present at start follow up) or inci-
dent (during follow-up; ipsilateral amputation, contralateral
amputation or both). We compared amputation rates between
patients with and without DM. To study the effect of amputa-
tion on mortality and also the potential effect of modification
by diabetes, we compared mortality rates in four groups:
patients without amputation and without DM (reference),
patients without amputation but with diabetes, patients with
amputation without diabetes and patients with both amputa-
tion and diabetes.
Statistical analysis
Baseline variables were compared between diabetes and non-
diabetes dialysis patients and expressed as a proportion or
mean with standard deviation (SD). For time-to-event analysis,
patients were censored at the time of the event under study
(amputation or death), renal transplant or end of follow-up (1
January 2007). The amputation rate was calculated as the inci-
dence rate and expressed as the number of amputations/100
person-years.
Mortality rates were compared with Poisson regression and
incidence rate ratios were estimated including 95% confidence
intervals (CIs). To estimate the effect of amputation on mortal-
ity, amputation was considered a time-dependent variable. The
potential interaction between amputation and diabetes was
assessed.
Effect estimates were adjusted for age, gender, dialysis mo-
dality, amputation at baseline, smoking, blood pressure, body
mass index, myocardial infarction or stroke in multivariable
models. Analyses were performed with SPSS statistical soft-
ware, version 20.0 (IBM, Armonk, NY, USA). Time-dependent
analyses were performed using Stata version 14.1 (StataCorp,
College Station, TX, USA).
RESULTS
Patient characteristics
Between January 1997 and January 2007, 2051 patients who
started renal replacement therapy were included in the
NECOSAD. Twenty-five percent of patients had DM at baseline
(Table 1). Sixty-four percent of diabetic patients were treated
with insulin injection therapy. Patients with diabetes were older
(mean age 63 6 13 years) compared with non-diabetics (59 6 16
years). Forty-six percent of diabetic patients had retinopathy for
which laser coagulation was performed. Seventy-one percent of
patients with diabetes had diabetes as their primary renal
disease.
HD was the dialysis modality in 68% of patients with DM and
63% of patients without DM. The prevalence of cardiovascular
morbidity at baseline was higher compared with patients with-
out DM. Peripheral artery disease was present in 19% of patients
with DM compared with 10% in patients without DM.
Amputation
At baseline, 24 of 413 diabetic patients (5.8%) had an amputation
compared with only 9 of 1553 non-diabetic patients (0.5%)
(Table 2). During follow-up (mean duration 2.9 6 2.3 years), 50
diabetic patients had a new amputation (12.1%) compared with
20 non-diabetic patients (1.2%). Amputation rates/1000 person-
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years were 47.9 (95% CI 36.3–63.2) and 4.1 (95% CI 2.7–6.4) for dia-
betic and non-diabetic patients, respectively. The level of ampu-
tation was different in both groups; patients with diabetes had
mainly minor amputations (5.1%), whereas patients without di-
abetes had mainly major extremity amputations (0.6%). After
the first amputation on dialysis therapy, almost 50% of patients
(24 of 50) with diabetes had a second amputation compared
with 20% (5 of 20) of patients without DM. The majority of
patients (37/50 diabetic patients with an amputation) used insu-
lin therapy.
Survival after amputation
In total, 911 patients (44%) died during follow-up. Fifty-four of
70 patients with a first amputation during dialysis therapy
died (77.1%). Four patients with an amputation and DM re-
ceived a renal transplant compared with no transplants in
patients with an amputation without DM. Other reasons for
censoring during follow-up (moving to an other centre, centre
stopped participation, other and refusal) were similar in both
groups.
Table 1. Baseline characteristics of patients with diabetes compared with patients without diabetes
Baseline characteristics Patients with diabetes (n¼ 413) Patients without diabetes (n¼1638)
Age at start of dialysis (years), mean (SD) 63 (13) 59 (16)
Gender (male), % 55 64
Primary renal disease, n (%)
DM 295 (71) 0
Glomerulonephritis 7 (2) 245 (15)
Renal vascular disease 46 (11) 309 (19)
All other 65 (16) 1084 (66)
Treatment modality (% HD) 68 63
Comorbidity, %
Cerebrovascular accident 13 6
Myocardial infarction 18 10
Severity of DM
Peripheral artery disease without amputation, % 19 10
Duration of DM (years), mean (SD) 16 (11) 0
Retinopathy (laser coagulation), % 46 0
Insulin dependency, % 64 0
Medication, %
Antihypertensive agents 85 70
Lipid-lowering medication 34 18
Smoking (currently or recently quit), % 20 29
Blood pressure (mmHg)
Systolic 153 (24) 148 (24)
Diastolic 79 (12) 84 (13)
Body mass index (kg/m2) 27 (5) 25 (4)
Laboratory values, mean (SD)
Cholesterol (mmol/L) 4.9 (1.4) 5.1 (1.3)
Haemoglobin (g/dL) 11.1 (1.6) 11.2 (1.6)
Calcium (mmol/L) 2.3(0.26) 2.4 (0.25)
Phosphate (mmo/L) 1.8 (0.53) 1.8 (0.55)
rGFR (mL/min/1.73 m2) 5.6 (3.5) 5.2 (3.6)
rGFR, residual glomerular filtration rate.
Table 2. Data on amputations
Amputation Patients with diabetes (n¼ 413) Patients without diabetes (n¼1638)
First amputation, n (%)
Baseline 24 (5.8) 9 (0.5)
During follow-up 50 (12.1) 20 (1.2)
Level of amputation (during follow-up), n (%)
Toe (minor) 21 (5.1) 6 (0.4)
Feet (minor) 8 (1.9) 1 (0.06)
Below knee (major) 16 (3.9) 9 (0.6)
Above knee (major) 5 (1.2) 4 (0.2)
Amputation rate/1000 person-years 47.9 4.1
Days to incident amputation, mean (SD) 511 (380) 671 (409)
Second amputation 24 5
Days to second amputation (from first amputation), mean (SD) 88 (91) 139 (148)
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Survival after amputation and diabetes status
Mortality was higher in patients with diabetes [HR 1.6 (95% CI
1.4–1.9)] compared with non-diabetic patients adjusted for age,
gender, amputation at baseline and dialysis modality.
Amputation increased mortality risk more than 4-fold in
patients without diabetes [HR 4.6 (95% CI 2.8–7.6)] as well as in
patients with diabetes [HR 4.6 (95% CI 3.3–6.4)] (Figure 1). Further
adjustment for smoking, blood pressure, body mass index, myo-
cardial infarction or stroke did not change these results sub-
stantially (Table 3). No formal interaction between diabetes and
amputation was found (P¼ 0.12 from likelihood ratio test),
meaning that mortality risk after amputation is high but coex-
isting DM does not add further to this risk.
In a subanalysis in patients with a major amputation, we
found no difference in the mortality risk in diabetic patients
compared with non-diabetic patients. The number of patients
with a minor amputation without DM was too small to perform
a subanalysis in patients with a minor amputation.
DISCUSSION
The results of this study demonstrate that the burden of non-
traumatic amputation in dialysis patients remains high, espe-
cially in patients with diabetes, with an incidence rate of
amputation of 4/100 person-years in diabetic patients compared
with 0.4/100 person-years in non-diabetic patients. We also
showed that amputation in this medically compromised patient
group is associated with a clearly increased mortality risk; this
mortality risk was similar for diabetic and non-diabetic
patients.
Survival among dialysis patients with DM is inferior to sur-
vival of non-diabetic dialysis patients [18–21], probably due to
the higher prevalence of diabetes-related comorbid conditions,
including foot ulceration and infection, neuropathy, peripheral
vascular disease and cardiovascular morbidity. These
comorbid conditions may also contribute to a higher incidence
of amputation in diabetic dialysis patients. One could hypothe-
size that these comorbid conditions also contribute to a de-
creased survival after amputation in dialysis patients with
diabetes compared with non-diabetic patients. However,
results of this study showed that mortality after amputation in
dialysis patients is high and DM does not further increase this
mortality risk.
Hoffstad et al. [22] showed that mortality risk after lower ex-
tremity amputation in a large population with DM but without
severe chronic kidney disease was 3-fold increased. They also
showed that some of this risk excess can be explained by well-
known complications of diabetes. The study and also our results
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FIGURE 1: Survival without amputation and after amputation in diabetic and non-diabetic patients.
Table 3. Poisson regression: effect of incident amputation and DM on mortality in ESRD
Patient group n Crude HR (95% CI) Adjusted HR (95% CI)a Adjusted HR (95 % CI)b
1. Amputation, DM 1618 1.0 (reference) 1.0 (reference) 1.0 (reference)
2. Amputation, DMþ 363 1.7 (1.5–2.0) 1.6 (1.4–1.9) 1.6 (1.4–1.9)
3. Amputationþ, DM 20 5.9 (3.6–9.8) 4.6 (2.8–7.6) 4.6 (2.8–7.5)
4. Amputationþ, DMþ 50 3.9 (2.8–5.5) 4.6 (3.2–6.4) 5.0 (3.5–7.2)
aModel adjusted for age, gender and amputation at baseline.
bModel adjusted for age, gender, amputation at baseline, dialysis modality, smoking, blood pressure, body mass index, myocardial infarction or stroke.
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mostly independent of coexisting conditions such as diabetes,
hypertension and the presence of cardiovascular disease.
Furthermore, the risk of a recurrent amputation in this study
was high, especially in patients with DM. Almost 50% of diabetic
patients received a recurrent amputation during follow-up,
which is in line with data from studies on diabetic patients
without ESRD [23, 24]. The number of patients who received a
recurrent amputation, however, was relatively small in this
study, and these results provide further confirmation in inde-
pendent cohorts with long-term follow-up.
There are some potential limitations that should be taken
into account when interpreting the data. First, data on glycae-
mic control were not available. However, data on the duration
of DM retinopathy for which laser coagulation therapy was per-
formed and insulin dependency was available, which also
reflects the severity of diabetes. As the patients in the NECOSAD
cohort are treated to prevailing diabetes guidelines, it is unlikely
that glycaemic control is structurally different from control in
other dialysis-based cohorts. Similar reasoning applies to car-
diovascular risk management. We thus consider our results
generalizable to other dialysis-based cohorts.
Second, the severity of peripheral vascular disease and infor-
mation about limb salvage therapy was not available. Third, by
the design of the study, data on amputations were extracted
from data on hospitalizations and surgery. Therefore we cannot
exclude that some patients with a minor amputation without
hospitalization were not included in this study. Another limita-
tion of this study, due to inadequate sample size, is that we
could not evaluate the number of patients in each subgroup of
level of amputation, especially in the subgroup with minor
amputations.
Although it is important to assess survival after amputation,
from a patient’s perspective it is also relevant to know what
quality of life will remain after amputation. Only a few studies
explored quality of life and/or functional outcomes after ampu-
tation on chronic dialysis therapy and reported a longer length
of stay in hospital [25] and lower functional independence mea-
sure scores after limb amputation compared with patients with-
out ESRD [26, 27]. Furthermore, quality of life is reduced [28, 29].
This shows that the combination of ESRD and amputation poses
a high disease burden on patients.
In order to reduce the number of amputations in dialysis
patients, further optimizing and/or implementing foot care
according to the international guidelines in the renal clinic is
essential [30]. Patients with ESRD are often dialysed in a renal
care unit separate from the diabetes care unit, thus regular foot
screening and foot care education might be suboptimal.
Implementation of monthly foot checks in renal care units was
associated with a reduction in major lower limb amputations in
diabetic incident HD patients [31].
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